Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 511 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Estrogen Receptor Negative Breast Cancer Clear all
Completed Phase 2 Interventional Results available

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

NCT00371345
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Dasatinib, Dasatinib 100 mg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Pre-Surgical Intervention for Targeted Therapies for Breast Cancer

NCT01004744
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Anastrozole
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

NCT00070564
View directory record Official record
Conditions
Breast Cancer
Interventions
pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
539
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Withdrawn Phase 2 Interventional

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

NCT02746328
View directory record Official record
Conditions
ER+ and AR+ Breast Cancer
Interventions
GTx-024 9 or 18 mg
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Avandamet
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 6, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT05827614
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Interventions
BBI-355, Erlotinib, Futibatinib, BBI-825
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study

NCT02229084
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Docetaxel
Biological · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733
View directory record Official record
Conditions
HR+ HER2- Breast Cancer
Interventions
Serabelisib, Sapanisertib, Fulvestrant
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
7
States / cities
Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

NCT01009437
View directory record Official record
Conditions
Breast Cancer
Interventions
ritonavir, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

NCT01963481
View directory record Official record
Conditions
Metastatic Beast Cancer
Interventions
Exemestane, Cyclophosphamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 6, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
Camizestrant, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 2 Interventional

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Endocrine therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
Interventions
Talimogene laherparepvec, Paclitaxel
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

NCT01238133
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 6, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

NCT02115048
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Letrozole, Afatinib
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700
View directory record Official record
Conditions
Prostate Cancer
Interventions
VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001, ACZ885, CJM112, TMT212, EGF816
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 6, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399
View directory record Official record
Conditions
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions
NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
Drug
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Duarte, California • La Jolla, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Early Phase 1 Interventional

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

NCT03962647
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer
Interventions
2-Week Ketogenic Diet, Letrozole
Dietary Supplement · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555
View directory record Official record
Conditions
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Berzosertib, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 6, 2026, 5:41 PM EDT
Completed No phase listed Observational

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

NCT00115505
View directory record Official record
Conditions
Breast Carcinoma
Interventions
quality-of-life assessment, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
227
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Fresno, California + 154 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

NCT01482156
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
Interventions
RAD001 + BEZ235
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Fayetteville, Arkansas • St Louis, Missouri • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Not applicable Interventional Results available

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

NCT01463007
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated partial breast irradiation, Extended Follow up
Radiation · Other
Lead sponsor
Jaroslaw Hepel
Other
Eligibility
50 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
4
States / cities
Lakeland, Florida • Providence, Rhode Island • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 6, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

NCT00856492
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
365
States / cities
Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 6, 2026, 5:41 PM EDT